行情

CRMD

CRMD

CORMEDIX
NASDAQ

实时行情|Nasdaq Last Sale

4.680
+0.060
+1.30%
盘后: 4.680 0 0.00% 17:47 09/16 EDT
开盘
4.590
昨收
4.620
最高
4.720
最低
4.500
成交量
12.28万
成交额
--
52周最高
18.80
52周最低
4.360
市值
1.78亿
市盈率(TTM)
-6.4013
分时
5日
1月
3月
1年
5年
BLCT、CRMD 和 COIN 即将到来的截止日期：Bronstein、Gewirtz & Grossman LLC
NEW YORK, NY / ACCESSWIRE / September 13, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links ...
ACCESSWIRE · 3天前
4 周内下跌 21.2%，这就是你应该购买 CorMedix (CRMD) 的原因
Zacks.com · 6天前
从昨天开始的 72 个最大的推动者
Gainers Mechel PAO (NYSE: MTL) shares climbed 56.3% to settle at $5.00 on Tuesday. The company recently reported Q2results, including a 43% quarter-over-quarter revenue growth.
Benzinga · 09/08 08:57
BRIEF-CorMedix Inc Faces Delays At Third-Party Contract Manufacturer
reuters.com · 09/07 13:55
为什么 CorMedix 股票在周二下跌？
Benzinga · 09/07 13:49
行业更新：医疗保健
MT Newswires · 09/07 13:01
CorMedix Inc. 宣布监管更新
CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update with respect to its resubmission time...
GlobeNewswire · 09/07 12:30
Cormedix Q2 每股收益 $(0.12) 超过 $(0.17) 估计
Cormedix (AMEX:CRMD) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.17) by 29.41 percent.
Benzinga · 08/12 20:27
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解CRMD最新的财务预测，通过CRMD每股收益，每股净资产，每股现金流等数据分析CORMEDIX近期的经营情况，然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测CRMD价格均价为21.25，最高价位29.00，最低价为10.00。
EPS
机构持股
总机构数: 94
机构持股: 1,250.38万
持股比例: 32.83%
总股本: 3,808.64万
类型机构数股数
增持
30
77.93万
建仓
10
32.23万
减持
21
30.31万
平仓
10
23.23万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.24%
制药与医学研究
+0.11%
高管信息
Non-Executive Chairman/Independent Director
Myron Kaplan
Chief Executive Officer/Director
Khoso Baluch
Chief Financial Officer/Executive Vice President
Matthew David
Executive Vice President/General Counsel
Phoebe Mounts
Executive Vice President
John Armstrong
Executive Vice President
Elizabeth Masson Hurlburt
Other
Thomas Nusbickel
Independent Director
Paulo Costa
Independent Director
Janet Dillione
Independent Director
Gregory Duncan
Independent Director
Alan Dunton
Independent Director
Steven Lefkowitz
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
CRMD 简况
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

微牛提供CorMedix Inc.(NASDAQ-CRMD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CRMD股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRMD股票基本功能。